CureVac said it will pursue European approval for its coronavirus vaccine candidate despite its disappointing overall efficacy results, arguing that the final analysis of its final-stage trial shows 77% protection against serious disease and full protection against hospitalization and death.
In early June, shares of the German biopharmaceutical company fell by about 50% after its provisional data showed an overall effectiveness of 47%, well below that of rivals Moderna and BioNTech, which also developed punctures of messenger ribonucleic acid (mRNA).
The final analysis of CureVac, listed on the Nasdaq, showed an overall effectiveness of 48% against Covid-19 of any severity and 53% against mild disease. In subjects between the ages of 18 and 60, he said the greater effectiveness against serious diseases meant he still had a pathway of approval for his CVnCoV vaccine from the European Medicines Agency.
“In this final analysis, CVnCoV demonstrates a strong public health value in fully protecting participants in the 18-60 age group study against hospitalization and death and 77% against moderate and severe illness , an effectiveness profile that we believe will be an important contribution to helping manage the Covid-19 pandemic and the spread of the dynamic variant, ”said Franz-Werner Haas, chief executive.
CureVac has argued that the performance of its mRNA vaccine, which it is producing with the help of pharmaceutical giant Bayer, was lower because it treated 15 different virus variants. About 86% of coronavirus cases in their trial came from strains listed by the World Health Organization as “variants of concern” or “variants of interest.” But more recent studies have shown even greater efficacy among other vaccines.
Haas said the CureVac trial, which studied 40,000 subjects in Europe and Latin America, would also provide valuable data on coronavirus variants. Almost none of its subjects suffered from the original coronavirus strain, while 11%, according to the company, were less explored variants.
Earlier this month, CureVac he told herThe Financial Times could seek regulatory approval for certain age groups, certain severity levels, or potentially as a reinforcement feature. He also insisted that a second-generation vaccine to combat virus variants, which he is developing with GlaxoSmithKline, should not be affected by the disappointing results of the original vaccine, as it is designed differently.